BioGenes GmbH of Berlin, a developer of antibodies, has been chosen as a partner of cNEUPRO, a research project funded by the European Union. The project focuses on analyzing neurodegenerative diseases and discovering novel biomarkers, in hopes of providing early and differential diagnosis of Alzheimer’s disease. The company will provide laboratory facilities and personnel to develop monoclonal antibodies against specific dementia biomarkers in blood and cerebrospinal fluid.